Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...
The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...
A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...
Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.
Ovarian cancer mortality rates have declined, but disparities persist across age, race, and geographic regions. Older women, non-Hispanic White women, and those in the Northeast and Midwest have ...
Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...
The result is a record 18 million cancer survivors in the US right now, a number expected to grow between 300,000 and 500,000 annually over the next 10 years. In turn, a cancer diagnosis is often no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback